Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.68 |
| ▸ | CLK1 | P49759 | 9/20 | 0.68 |
| ▸ | KIF20A | O95235 | 10/20 | 0.66 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.56 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2726582 | 1.00 | DYRK1A (0.68) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL2726034 | 0.88 | KIF20A (0.66) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL2726037 | 0.88 | KIF20A (0.66) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL2725443 | 0.88 | DYRK1A (0.65) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL19179037 | 0.82 | DYRK1A (0.68) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL19179038 | 0.82 | DYRK1A (0.68) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL2711280 | 0.82 | DYRK1A (0.78) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL2711278 | 0.82 | DYRK1A (0.78) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL30937474 | 0.82 | DYRK1A (0.78) | DYRK1ACLK1KIF20ACLK2CLK4 | |
| SCHEMBL2725098 | 0.81 | DYRK1A (0.76) | DYRK1ACLK1KIF20ACLK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | claimed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | claimed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | claimed |
| US-8703808-B2 | Use of derivatives of indoles for the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-04-22 | — | — | US | claimed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | claimed |
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | disclosed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-8703808-B2 | Use of derivatives of indoles for the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2445497-A2 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010150211-A2 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-29 | — | — | WO | disclosed |
| EP-2266562-A1 | Use of derivatives of indoles for the treatment of cancer | Centre National de la Recherche Scientifique (FR) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | DYRK1A 597/4885CLK1 3098/4885KIF20A 871/4885 |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | DYRK1A 597/4885CLK1 3098/4885KIF20A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.